Cagrilintide vs Tirzepatide
Extensively Studied vs FDA Approved
compatible No known direct interactions; different mechanisms allow concurrent use.
Molecular Data
Cagrilintide Tirzepatide
Weight 4,409.01 Da 4,813.55 Da
Half-life ~7 days (159-195 hours) ~5 days (120 hours)
Chain 37 amino acids 39 amino acids
Type Amylin receptor agonist Dual GLP-1/GIP agonist
Key Benefits
Cagrilintide
01 FDA development candidate with extensive Phase 3 data
02 Superior weight loss in combination with semaglutide (22.7%)
03 Once-weekly convenience
04 2.2% HbA1c reduction with CagriSema
Tirzepatide
01 Dramatic weight loss (15-22% body weight)
02 Superior diabetes control
03 Reduced cardiovascular risk (26% reduction in MACE)
04 Improved insulin sensitivity
05 Appetite suppression
06 Preserved muscle mass with exercise
Dosing Protocols
Cagrilintide
2.4mg weekly (after escalation) / Once weekly, same day each week
Weight Loss (Monotherapy) 2.4mg Once weekly
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly
Type 2 Diabetes Management 2.4mg weekly Once weekly
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks
Tirzepatide
2.5mg starting, titrate up to 5-15mg weekly / Once weekly (same day each week)
Weight loss initiation 2.5mg Once weekly x 4 weeks
Weight loss progression 5mg Once weekly
Weight loss optimization 7.5-10mg Once weekly
Maximum weight loss 12.5-15mg Once weekly
Diabetes management (mild) 5-7.5mg Once weekly
Diabetes management (severe) 10-15mg Once weekly
Side Effects
Cagrilintide
Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Tirzepatide
Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings
Contraindications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Cagrilintide Tirzepatide
Status Extensively Studied FDA Approved
References 3 studies 4 studies
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.